Prosecution Insights
Last updated: November 20, 2026
Application No. 19/221,402

Systems And Methods For Semi-Quantitative And Quantitative Detection Of Metabolities Of Progesterone

Non-Final OA §103§DP
Filed
May 28, 2025
Priority
May 28, 2024 — provisional 63/652,529
Examiner
WHITE, DENNIS MICHAEL
Art Unit
1758
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Easy Healthcare Corporation
OA Round
3 (Non-Final)
58%
Grant Probability
Moderate
3-4
OA Rounds
1y 6m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allowance Rate
487 granted / 839 resolved
-7.0% vs TC avg
Strong +48% interview lift
Without
With
+48.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
23 currently pending
Career history
871
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
45.2%
+5.2% vs TC avg
§102
28.0%
-12.0% vs TC avg
§112
14.5%
-25.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 839 resolved cases

Office Action

§103 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 1/29/2026 has been entered. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-4, are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 3, 8, 10, 12, 14, and 20 of U.S. Patent No. 11,519,909 in view of Busa (US 2021/0364536). Regarding claims 1, 14 of US 11519909 (corresponds to current claims 1, 3), as claiming a testing system comprising: a test device that including a visually identifiable test line and a visually identifiable control line formed in response to exposure to a tested substance; and a user device including a camera, a processor, a display, and memory storing program instructions, wherein, in response to executing the program instructions, the processor: receives an image of the test device from the camera, the image including a visually identifiable test-line and a visually identifiable control-line; determines a test-line value defined as a numerical value of a color density of the test-line in the image; determines a control-line value defined as a numerical value of a color density of the control-line in the image; and calculates a T/C ratio defined as a relative value of the test-line value to the control-line value; wherein, in response to executing the program instructions, the processor further: compares the T/C ratio for a user for a plurality of days during at least one complete menstrual cycle; determines a peak T/C ratio for the menstrual cycle; and presents information indicative of the peak T/C ratio through the display. US 11519909 claim 1 fails calibration chart including a plurality of color blocks, wherein each of the color blocks is representative of a test-line color density that corresponds to a quantitative hormone concentration in the target substance. US 11519909 further discloses calibration chart to correlate the hormone level concentration to the T/C ratio (Fig. 2-3: data structure 118a, 118b color intensity ratio T/C corresponding concentration of the LH hormone level). Combining prior art elements according to known methods to yield predictable results is known. Therefore it would have been obvious to one of ordinary skill in the art to combine the calibration chart in Fig. 2-3 to provide the correlation from the T/C ratio to the concentration of the analyte to provide a quantitative analysis. US 11519909 is silent to a tangible calibration chart including a plurality of color blocks, wherein each of the color blocks is a physical embodiment of a test-line color density. Busa et al teach a lateral flow test device cartridge 20 and a calibration test pattern 200 that is affixed as a sticker or insert at a designated location on the tray 32 to be used to calibrate the test pattern intensities of the test strip (Para. 0082, Fig. 5). It is desirable to provide the calibration test pattern as a physical/tangible sticker or insert to enable the reader to perform a self-test immediately before the test strip of the cartridge itself is read. Combining prior art elements according to known methods to yield predictable results is known. Therefore it would have been obvious to one of ordinary skill in the art to combine the teaching of a physical/tangible sticker or insert of the calibration chart of Busa to the calibration chart of Liu to provide the above advantage of enabling the reader to perform a self-test immediately before the test strip of the cartridge itself is read. Regarding claim 3 of US 11519909 (corresponds to current claims 2) as claiming the test device is a rapid lateral flow immunoassay test device that is one of an ovulation, pregnancy, progesterone, estrogen, estriol, and follicle-stimulating hormone test device, but the claim 3 does not recite one or more progesterone metabolite. US 11519909 further discloses one or more progesterone metabolite (col. 10 lines 19: progesterone or its metabolites) . It is obvious to provide the detection of progesterone as analytes of interest related to fertility. Combining prior art elements according to known methods to yield predictable results is known. Therefore it would have been obvious to one of ordinary skill in the art to combine the analyte of progesterone or its metabolites to provide the above advantage of analyzing fertility related analytes. Regarding claims 8, 10, 12, 20 of US 11519909 (corresponds to current claims 4) as claiming the processor determines the color density of the test-line and the color density of the control-line using a color model that represents color density with a numeric value; the memory stores a data structure that relates T/C ratio to quantitative levels of a substance being tested; the T/C ratio is translated into a quantitative level of a substance. Claims 1-4 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 3, 8, 10, 12, 14, and 20 of U.S. Patent No. 12,287,293 in view of Busa (US 2021/0364536). Regarding claims 1,14 of 12287293 (corresponds to current claim 1, 3, 4) claims a testing system comprising: a test device including a test area including a visually identifiable test-line and a visually identifiable control-line formed in response to exposure to a tested substance; and a user device including a camera, a processor, a display, and memory storing program instructions, wherein, in response to executing the program instructions, the processor: receives an image of the test device from the camera, the image including the test area, the visually identifiable test-line, and the visually identifiable control-line; determines a numerical test-line value and a numerical control-line value based on the visually identifiable test-line and the visually identifiable control-line, respectively; calculates a T/C ratio defined as a relative value of the numerical test-line value to the numerical control-line value; translates the T/C ratio into a quantitative level of an analyte in the tested substance; analyzes data points, wherein the data points include the T/C ratio and/or quantitative level of the analyte and additional T/C ratios and/or additional quantitative levels of other analytes; and presents information indicative of the data points, wherein the information includes a calendar and/or a graph including an ovulation cycle and/or hormone changes. US 12287293 fails to claim the calibration chart including a plurality of color blocks, wherein each of the color blocks is representative of a test-line color density that corresponds to a quantitative hormone concentration in the target substance. US 12287293 further discloses calibration chart to correlate the hormone level concentration to the T/C ratio (Fig. 2-3: data structure 118a, 118b color intensity ratio T/C corresponding concentration of the LH hormone level). Combining prior art elements according to known methods to yield predictable results is known. Therefore it would have been obvious to one of ordinary skill in the art to combine the calibration chart in Fig. 2-3 to provide the correlation from the T/C ratio to the concentration of the analyte to provide a quantitative analysis. US 12287293 is silent to a tangible calibration chart including a plurality of color blocks, wherein each of the color blocks is a physical embodiment of a test-line color density. Busa et al teach a lateral flow test device cartridge 20 and a calibration test pattern 200 that is affixed as a sticker or insert at a designated location on the tray 32 to be used to calibrate the test pattern intensities of the test strip (Para. 0082, Fig. 5). It is desirable to provide the calibration test pattern as a physical/tangible sticker or insert to enable the reader to perform a self-test immediately before the test strip of the cartridge itself is read. Combining prior art elements according to known methods to yield predictable results is known. Therefore it would have been obvious to one of ordinary skill in the art to combine the teaching of a physical/tangible sticker or insert of the calibration chart of Busa to the calibration chart of Liu to provide the above advantage of enabling the reader to perform a self-test immediately before the test strip of the cartridge itself is read. Regarding claim 4,17 of 12287293 (corresponds to current claim 4) claims comprising a plurality of test devices, each test device including a test area including a visually identifiable test-line and a visually identifiable control-line formed in response to exposure to a tested substance, wherein the processor is configured to: receive a plurality of images of the test devices from the camera, each image including the test area, the visually identifiable test-line, and the visually identifiable control-line; determine a numerical test-line value and a numerical control-line value based on the visually identifiable test-line and the visually identifiable control-line, respectively, for each image; calculate a T/C ratio for each image, the T/C ratio defined as a relative value of the numerical test-line value to the numerical control-line value; translate each T/C ratio into a quantitative level of an analyte in the tested substance, wherein the data points include each T/C ratio and/or quantitative level; and present the information indicative of the data points. Regarding claim 7, 13, 20, 25 of US 12287293 (corresponds to current claims 2) as claiming test device is one of an ovulation, pregnancy, progesterone, estrogen, estriol, follicle-stimulating hormone, or other hormone or chemical analyte test device, but the claim 7 does not recite one or more progesterone metabolite. US 12287293 further discloses one or more progesterone metabolite (col. 10 lines 19: progesterone or its metabolites) . It is obvious to provide the detection of progesterone as analytes of interest related to fertility. Combining prior art elements according to known methods to yield predictable results is known. Therefore it would have been obvious to one of ordinary skill in the art to combine the analyte of progesterone or its metabolites to provide the above advantage of analyzing fertility related analytes. Claim Rejections - 35 USC § 103 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claim(s) 1-7, 9 is/are rejected under 35 U.S.C. 103 as being unpatentable over Liu et al (US 2021/0373010) in view of Busa (US 2021/0364536). Regarding claims 1, Liu et al teach a test system comprising: a test device (Fig 1: 104) including a test area (Fig. 1: 105), a results area (Fig. 1: T-line 109), and a control area (Fig. 1: C-line 111), wherein the test area of the body includes a lateral flow assay that detects the presence of a target analyte in a target substance, wherein, in response to exposure to the target analyte, the results area produces a visually identifiable test-line having a test-line color density (Fig. 1: T-line 109) and a visually identifiable control-line having a control-line density (Fig. 1: C-line 111), wherein the visually identifiable test- line increases in darkness according to an increased concentration level of the target analyte (Para. 0007: darker shade increased concentration); and a calibration chart including a plurality of color blocks, wherein each of the color blocks is representative of a test-line color density that corresponds to a quantitative hormone concentration in the target substance (Para. 0072, Fig. 2-3: data structure 118a, 118b color intensity ratio T/C corresponding concentration of the LH hormone level). Liu et al is silent to the calibration chart is tangible and a physical embodiment. Busa et al teach a lateral flow test device cartridge 20 and a calibration test pattern 200 that is affixed as a sticker or insert at a designated location on the tray 32 to be used to calibrate the test pattern intensities of the test strip (Para. 0082, Fig. 5). It is desirable to provide the calibration test pattern as a physical/tangible sticker or insert to enable the reader to perform a self-test immediately before the test strip of the cartridge itself is read. Combining prior art elements according to known methods to yield predictable results is known. Therefore it would have been obvious to one of ordinary skill in the art to combine the teaching of a physical/tangible sticker or insert of the calibration chart of Busa to the calibration chart of Liu to provide the above advantage of enabling the reader to perform a self-test immediately before the test strip of the cartridge itself is read. Regarding claim 2, Liu/Busa teach the test area is a non-competitive lateral flow assay for determining the concentration of the target analyte (Para. 0056: lateral flow assay T/C ratio directly correlates to the concentration of the analyte LH), wherein the target analyte is one or more progesterone metabolite (Para. 0060: progesterone or its metabolites). Regarding claims 3, Liu/Busa teach a user device including a camera, a processor, a display, and memory storing program instructions (Para. 0026), wherein, in response to executing the program instructions, the processor: receives an image of the test area from the camera, the image including the visually identifiable test-line and the visually identifiable control-line; determines a test-line value defined as a numerical value of a color density of the test-line in the image; determines a control-line value defined as a numerical value of a color density of the control-line in the image (Para. 0026-0027); and calculates a quantitative hormone concentration in the target substance using the numerical value of the color density of the test-line in the image and the numerical value of the color density of the control-line in the image. (Para. 0074-0075, Fig. 2-3, claim 1) Regarding claim 4, Liu/Busa teach calculating a quantitative hormone concentration in the target substance using the numerical value of the color density of the test-line in the image and the numerical value of the color density of the control-line in the image, includes: calculating a T/C ratio defined as a relative value of the test-line value to the control-line value (Claim 1); and determining a quantitative hormone level based on the comparison between the T/C ratio and a data structure that maps calibrated T/C ratios to quantitative hormone levels. (Para. 0074-0075, Fig. 2-3, claim 1) Regarding claim 5, Liu/Busa teach in response to executing the program instructions, the processor further presents visualized data through the display indicative of one or more T/C ratio trends or one or more quantitative hormone level trends (Fig. 9; Para. 0017). Regarding claim 6, Liu/Busa teach a user device including a processor, a display, and memory storing program instructions (claim 1), wherein, in response to executing the program instructions, the processor: receives quantitative hormone levels at one or more specific stages of a menstrual cycle or a pregnancy derived from the test device and calibration chart; and compares the quantitative hormone levels at one or more specific stages of a menstrual cycle or a pregnancy to one or more normal hormone level trends (Para. 0017; Fig. 9). Regarding claim 7, Liu/Busa teach the processor further compares the quantitative hormone levels at one or more specific stages of a menstrual cycle or a pregnancy to one or more threshold values associated with risk levels of certain health condition, wherein the one or more threshold values associated with risk levels of one or more health conditions are determined based on scientific research and data analysis in combination with a user's personalized data (Para 0018-0019: associated with progesterone levels). Regarding claim 9, Liu/Busa teach the display provides an indication of a potential health condition risk derived from a comparison between the quantitative hormone levels at one or more specific stages of a menstrual cycle or a pregnancy derived from the test device and calibration chart and one or more normal hormonal level trends. (Para. 0076: low or high hormone levels displayed) Claim(s) 8 is/are rejected under 35 U.S.C. 103 as being unpatentable over Liu/Busa in view of Nazareth et al (US 2013/0065321). Regarding claim 8, Liu et al teach associated progesterone levels (Para. 0018,0028). It is noted that progesterone levels are associated with one or more health conditions include: a miscarriage, an ectopic pregnancy, an ovarian tumor, or an adrenal gland problem. (See current Specification Para. 0003, 0034, 0047, 0071). Liu are silent to associating the progesterone levels with ectopic or miscarriages. Nazareth et al teach a kit for monitoring analyte levels in a fluid sample. Nazareth teach progesterone levels indicate ectopic and miscarriages (Para. 0068). It is desirable to associate progesterone levels with health conditions such as miscarriages and ectopic pregnancies to provide warnings of potential health risks. Combining prior art elements according to known methods to yield predictable results is known. Therefore it would have been obvious to one of ordinary skill in the art to combine the hormone levels of progesterone with one or more health conditions include: a miscarriage, an ectopic pregnancy, an ovarian tumor, or an adrenal gland problem to provide the above advantage of providing warnings of potential health risks. Response to Arguments Applicant arguments regarding the Double Patenting rejection are persuasive but the Double Patenting rejection is upheld in view of the new Double Patenting rejection in view of Busa (US 2021/0364536). Applicant’s arguments with respect to claim(s) 1-9 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to DENNIS MICHAEL WHITE whose telephone number is (571)270-3747. The examiner can normally be reached M-F 8:30am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Maris R. Kessel can be reached at (571) 270-7698. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Dennis White/Primary Examiner, Art Unit 1758
Read full office action

Prosecution Timeline

Show 1 earlier event
Jul 10, 2025
Non-Final Rejection mailed — §103, §DP
Oct 10, 2025
Response Filed
Oct 29, 2025
Final Rejection mailed — §103, §DP
Jan 29, 2026
Request for Continued Examination
Feb 01, 2026
Response after Non-Final Action
Sep 17, 2026
Non-Final Rejection mailed — §103, §DP
Nov 18, 2026
Applicant Interview (Telephonic)
Nov 18, 2026
Examiner Interview Summary

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12800602
SAMPLE PRE-TREATMENT SYSTEM
3y 10m to grant Granted Nov 17, 2026
Patent 12791565
METABOLIC PROFILE SCREENING FOR GESTATIONAL DIABETES
4y 7m to grant Granted Nov 10, 2026
Patent 12773690
A POINT OF CARE DEVICE
3y 11m to grant Granted Oct 27, 2026
Patent 12761175
METHOD AND APPARATUS FOR REMOTE MONITORING OF VARIOUS ORGANIC COMPOUNDS
3y 2m to grant Granted Oct 13, 2026
Patent 12754179
Vertical Flow Assay Device and Method for Determination of Hemoglobin Concentration
3y 9m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
58%
Grant Probability
99%
With Interview (+48.4%)
3y 0m (~1y 6m remaining)
Median Time to Grant
High
PTA Risk
Based on 839 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month